Alcohol-related%20liver%20disease Patient Education

Patient Education

Lifestyle Modification

Abstinence from Alcohol

Cornerstone of long-term management of alcohol-related liver disease (ALD)
Though the safe alcohol consumption level continues to be reviewed, patients with no liver disease should be advised to take no more than 2 standard drinks/day for males and no more than 1 standard drink/day for females
- Patients with ALD or other liver diseases (eg NASH, NAFLD, viral hepatitis and hemochromatosis) should be advised to completely abstain from alcohol
Educate the patient regarding the nature of the disease and the benefit of discontinuing alcohol intake
- Abstinence or marked reduction in alcohol intake has been shown to improve histology and/or survival in all stages of ALD
  - Abstinence can cause total resolution of alcoholic steatosis and improve long-term prognosis in alcoholic hepatitis
  - Risk of liver-related complications and mortality is reduced following complete alcohol abstinence in patients with alcohol-related cirrhosis
Assistance should be given to the patient to help them change their behavior
- Psychosocial and behavioral approaches may include counseling, group therapies or inpatient rehabilitation
- Other modalities include cognitive behavioral therapy, motivational interviewing or motivational enhancement therapy
Patient may require consultation with a psychiatrist or addiction specialist
Disulfiram, Naltrexone and Acamprosate are approved abstinence and relapse prevention medications for patients with alcohol use disorder (AUD)
- Due to their potential for hepatotoxicity, Disulfiram and Naltrexone should be avoided in patients with ALD
Nalmefene is approved in Europe for reduction of heavy drinking in AUD and may be considered when abstinence is not feasible in patients with early-stage liver disease
Baclofen is used in patients with moderate alcohol withdrawal symptoms and to prevent alcohol relapse in patients with advanced ALD
Benzodiazepines are used in patients with moderate and severe alcohol withdrawal syndrome
- Due to its potential for abuse and/or encephalopathy, benzodiazepines should not be given for >10-14 days

Other Lifestyle Modifications

Smoking Cessation

Smoking may increase rate of progression of fibrosis in ALD
Patients should be encouraged to stop smoking

Obese Patients

Body mass index (BMI) has been shown to be an independent risk factor for ALD development
Physical activity and exercise are encouraged in obese patients

Product Highlight - OZEMPIC

16 Sep 2020

OZEMPIC – Semaglutide 1.34 mg/mL soln for inj

Reducing risks and improving long-term outcomes in patients with CHB

Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019

Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).